The largest COVID vaccine study to date, analyzing 99 million vaccinated individuals across eight countries, found a slight increase in neurological, blood, and heart-related medical conditions associated with the vaccine, including a higher risk of myocarditis with mRNA vaccines and blood clots in the brain with viral-vector vaccines. The study also identified an increased likelihood of Guillain-Barre syndrome and other rare potential vaccine safety signals. Experts emphasize that while these risks are rare, the benefits of vaccination in reducing the risk of severe COVID-19 outweigh them, and urge careful consideration of risks and benefits by both patients and healthcare providers.
The largest COVID vaccine study to date, conducted by the Global Vaccine Data Network in New Zealand, analyzed 99 million vaccinated individuals across eight countries and found a slight increase in neurological, blood, and heart-related medical conditions associated with the vaccine, including myocarditis and blood clots in the brain. The study also identified an increased likelihood of Guillain-Barre syndrome and other rare potential vaccine safety signals. Experts emphasize that while these risks are rare, the benefits of vaccination in reducing the risk of COVID outweigh them, and urge a careful risk/benefit analysis for each individual.
The largest global vaccine safety study to date found small increases in neurological, blood, and heart-related conditions linked to Covid-19 vaccines, including heart-related inflammation from mRNA shots and an increased risk of blood clots and neurological disorders from viral-vector vaccines. While over 13.5 billion doses of Covid vaccines have been administered globally, saving over 1 million lives in Europe alone, a small proportion of people immunized were injured by the shots, sparking debate about their benefits versus harms. Additionally, a separate study conducted by the Yale School of Medicine identified common symptoms in adults experiencing chronic post-vaccination syndrome, which aims to understand the condition and improve vaccine safety.
